If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. We can accept comments from individuals. These will be considered, but you won’t get a formal ...

Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...

Tirzepatide has been studied in weight management in 2 large, phase 3 studies: SURMOUNT‑1 (n=2,539) in people who did not have diabetes and SURMOUNT‑2 (n=938) in people with type 2 diabetes. Both ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

A list of downloadable documents created during development.

NICE has produced a resource impact assessment tool for tirzepatide. NICE estimates that the total eligible population is 3.4 million people, and expects that an interim NHS England commissioning ...

Tirzepatide (Mounjaro, Eli Lilly) is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist for subcutaneous injection with a ...

Tirzepatide should be thought about as an option for individual people in line with NICE's guideline on overweight and obesity management. The visual summary care pathway has an overview. Table 4 is ...

NICE's medicines practice guideline on developing and updating local formularies recommends that medicines recommended in NICE technology appraisals are adopted into local formularies automatically ...